News|Podcasts|November 17, 2026

Don't Miss a Beat: How Prediction Markets Could Threaten Clinical Trial Integrity

Fact checked by: Patrick Campbell

Ankeet Bhatt, MD, MBA, ScM, joins Don't Miss a Beat at AHA 2026 to discuss how betting on clinical trials could affect participant retention and integrity.

Welcome back to Don't Miss a Beat!

Prediction markets have moved into clinical research, with Kalshi launching a pilot in July 2026 of contracts on whether late-stage trials meet their preregistered primary endpoints.1 The expansion places event contracts, long used for sports and politics, alongside ongoing studies built on the altruism of volunteer participants.

In this episode of Don't Miss a Beat, recorded at the American Heart Association (AHA) Scientific Sessions 2026, hosts Muthiah Vaduganathan, MD, MPH, and Stephen Greene, MD, welcomed Ankeet Bhatt, MD, MBA, ScM. Bhatt, a cardiologist and research scientist at Kaiser Permanente Northern California, outlined how these markets could affect clinical trial integrity.

Insider information is the most obvious concern, but the deeper issue lies in the participant relationship. Volunteers accept risk over months or years, often for benefits realized long after their involvement ends, and a public betting line could shake their commitment.

A falling probability may lead participants to question whether a sponsor will keep funding the study, or to withdraw altogether. A rising probability carries its own risk, particularly in cardiovascular, renal, and metabolic medicine, where participants may seek similar approved therapies outside the trial. Either pattern erodes retention and the reliability of the final result.

Kalshi lists contracts only after enrollment closes and excludes patients, hospital workers, and pharmaceutical employees from trading.1,2 Enrollment is only the start, however, since participants still attend visits and outcomes are still being measured while contracts trade.1 A fully enrolled trial with poor retention can consume years of effort and participant risk without producing an answer.

Absent central regulation, protections may need to come from trialists themselves. Proposed steps include barring anyone with vested knowledge of a trial from these markets, addressing the issue in informed consent, and keeping market signals away from endpoint committees and data and safety monitoring boards.

The public interest driving these markets may also offer an opening. Responsible transparency about ongoing development programs could channel this curiosity toward trial participation in the US, where enrollment has lagged, rather than wagering from the outside.

References
  1. Yang YT, Kesselheim AS. Ban bets on unfinished clinical trials. Science. 2026;393(6817):1171. doi:10.1126/science.ael8642
  2. Kalshi's drug trial bets raise alarm over ethics, insider trades. Bloomberg Law. September 16, 2026. Accessed November 17, 2026. https://news.bloomberglaw.com/securities-law/kalshis-drug-trial-bets-raise-alarm-over-ethics-insider-trades

Related to this article